New drug combo tested for Tough-to-Treat lung cancer
NCT ID NCT07465757
Summary
This study is testing whether a new oral drug, alisertib, is safe and tolerable when given alongside the chemotherapy drug paclitaxel for adults with small cell lung cancer that has progressed after initial treatments. Researchers will give increasing doses of alisertib to small groups of about 50 participants to find the best dose with manageable side effects. The main goal is to understand the safety of this combination, while also checking if it helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.